Skip to main content
. Author manuscript; available in PMC: 2016 May 18.
Published in final edited form as: Oncogene. 2015 Apr 13;35(4):459–467. doi: 10.1038/onc.2015.97

Fig. 7. Treatment of cancer cells with PLX4032 confers resistance to TRAIL-dependent killing by activated human T cells.

Fig. 7

A and B, A375 or LOXIMVI cells pretreated with or without 5 μM (A375) or 2.5 μM (LOXIMVI) PLX4032 for 16 h were co-cultured with activated human T cells (cancer cells/T cells = 1:3). After 24 h, the T cells were gently removed from the culture system, and the adherent melanoma cells were subjected to MTT assay. Cell survival rates were also calculated in comparison with the control groups without T cells (right panels). Data are means ± SDs of four replicate determinations. C. A375 cells were co-cultured with activated human T cells pre-treated with or without an anti-TRAIL neutralizing antibody. After 24 h co-culture, T cells were gently removed and adherent A375 cells were subjected to MTT assay. Data are means ± SDs of four replicate determinations.